Cargando…
Cost-Utility Analysis: Current Methodological Issues and Future Perspectives
The use of cost–effectiveness as final criterion in the reimbursement process for listing of new pharmaceuticals can be questioned from a scientific and policy point of view. There is a lack of consensus on main methodological issues and consequently we may question the appropriateness of the use of...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Research Foundation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113167/ https://www.ncbi.nlm.nih.gov/pubmed/21713127 http://dx.doi.org/10.3389/fphar.2011.00029 |
_version_ | 1782205894318096384 |
---|---|
author | Nuijten, Mark J. C. Dubois, Dominique J. |
author_facet | Nuijten, Mark J. C. Dubois, Dominique J. |
author_sort | Nuijten, Mark J. C. |
collection | PubMed |
description | The use of cost–effectiveness as final criterion in the reimbursement process for listing of new pharmaceuticals can be questioned from a scientific and policy point of view. There is a lack of consensus on main methodological issues and consequently we may question the appropriateness of the use of cost–effectiveness data in health care decision-making. Another concern is the appropriateness of the selection and use of an incremental cost–effectiveness threshold (Cost/QALY). In this review, we focus mainly on only some key methodological concerns relating to discounting, the utility concept, cost assessment, and modeling methodologies. Finally we will consider the relevance of some other important decision criteria, like social values and equity. |
format | Online Article Text |
id | pubmed-3113167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Frontiers Research Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-31131672011-06-27 Cost-Utility Analysis: Current Methodological Issues and Future Perspectives Nuijten, Mark J. C. Dubois, Dominique J. Front Pharmacol Pharmacology The use of cost–effectiveness as final criterion in the reimbursement process for listing of new pharmaceuticals can be questioned from a scientific and policy point of view. There is a lack of consensus on main methodological issues and consequently we may question the appropriateness of the use of cost–effectiveness data in health care decision-making. Another concern is the appropriateness of the selection and use of an incremental cost–effectiveness threshold (Cost/QALY). In this review, we focus mainly on only some key methodological concerns relating to discounting, the utility concept, cost assessment, and modeling methodologies. Finally we will consider the relevance of some other important decision criteria, like social values and equity. Frontiers Research Foundation 2011-06-08 /pmc/articles/PMC3113167/ /pubmed/21713127 http://dx.doi.org/10.3389/fphar.2011.00029 Text en Copyright © 2011 Nuijten and Dubois. http://www.frontiersin.org/licenseagreement This is an open-access article subject to a non-exclusive license between the authors and Frontiers Media SA, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and other Frontiers conditions are complied with. |
spellingShingle | Pharmacology Nuijten, Mark J. C. Dubois, Dominique J. Cost-Utility Analysis: Current Methodological Issues and Future Perspectives |
title | Cost-Utility Analysis: Current Methodological Issues and Future Perspectives |
title_full | Cost-Utility Analysis: Current Methodological Issues and Future Perspectives |
title_fullStr | Cost-Utility Analysis: Current Methodological Issues and Future Perspectives |
title_full_unstemmed | Cost-Utility Analysis: Current Methodological Issues and Future Perspectives |
title_short | Cost-Utility Analysis: Current Methodological Issues and Future Perspectives |
title_sort | cost-utility analysis: current methodological issues and future perspectives |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113167/ https://www.ncbi.nlm.nih.gov/pubmed/21713127 http://dx.doi.org/10.3389/fphar.2011.00029 |
work_keys_str_mv | AT nuijtenmarkjc costutilityanalysiscurrentmethodologicalissuesandfutureperspectives AT duboisdominiquej costutilityanalysiscurrentmethodologicalissuesandfutureperspectives |